Cardiac Science and Quinton to Present Merger Information to Investment Community
March 07 2005 - 1:28PM
PR Newswire (US)
Cardiac Science and Quinton to Present Merger Information to
Investment Community Presentation Materials Will Be Available on
Their Websites IRVINE, Calif. and BOTHELL, Wash., March 7
/PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a
leading manufacturer of life-saving automatic public-access
defibrillators, and Quinton Cardiology Systems, Inc. (NASDAQ:QUIN),
a global leader in advanced cardiology products, today announced
that Cardiac Science Chairman and CEO Raymond W. Cohen and Quinton
President and CEO John R. Hinson are scheduled to make joint
presentations to institutional investors and others in the
investment community this week and during the next several weeks
relating to the proposed merger of Cardiac Science and Quinton. The
presentation materials used in conjunction with these presentations
will be made available on the websites of both companies,
http://www.cardiacscience.com/ and http://www.quinton.com/, by 5:00
p.m. EST on Tuesday, March 8, 2005; filed with the Securities and
Exchange Commission; and publicly available at its website,
http://www.sec.gov/. Presentation materials will include, among
other things, a summary of both companies businesses, the strategic
and financial reasons for the merger and the general benefits to
shareholders of the combination. About Quinton Cardiology Systems
Quinton, with operations in Bothell, WA, Deerfield, WI and
Shanghai, China, develops, manufactures, markets and services a
family of advanced cardiology products such as electrocardiographs,
cardiac stress test systems, Holter monitors, cardiac
rehabilitation telemetry systems, and cardiology data management
systems used in the diagnosis, monitoring and management of
patients with cardiovascular disease. Quinton markets its products
under the Quinton(R) and Burdick(R) brand names. In the U.S.,
Quinton products are sold to hospitals and the physician office
market through a 55-person sales organization, as well as through
multiple national and regional distributors. Internationally,
Quinton products are marketed by independent distributors in over
90 countries around the world. In 2004, Quinton was recognized by
the Puget Sound Business Journal as one of the ten fastest growing
public companies in Washington State. For more information, please
visit http://www.quinton.com/ or contact Quinton at (425) 402-2009.
About Cardiac Science Cardiac Science, with operations in Irvine
and Lake Forest, CA, Minneapolis, MN, Manchester, England and
Copenhagen, Denmark, develops, manufactures and markets
Powerheart(R)-brand automatic public-access defibrillators (AEDs)
and offers comprehensive AED/CPR training and AED program
management services that facilitate successful deployments. Cardiac
Science also makes the Powerheart(R) CRM(TM), the only FDA-cleared
therapeutic patient monitor that instantly and automatically treats
hospitalized cardiac patients who suffer life-threatening heart
rhythms. In the U.S., Cardiac Science products are sold to
corporations, police and fire departments, state and local
municipalities, the federal government and schools by its 55-person
direct sales force, and certain national and local distributors.
Internationally, Cardiac Science products are sold direct in the
United Kingdom and by independent distributors in over 50
countries. Cardiac Science also manufactures its AED products on a
private label basis for other leading medical companies such as
Quinton Cardiology Systems, Nihon Kohden (Japan) and GE Healthcare.
In 2004, Cardiac Science was recognized by Deloitte & Touche as
the 4th fastest growing technology company in North America and as
the fastest growing company in Orange County, CA. For more
information, please visit http://www.cardiacscience.com/ or contact
Cardiac Science at (949) 797-3800. Where to Find Additional
Information about the Merger Under the terms of the merger
agreement, the parties have formed a new corporation, CSQ Holding
Company, and two wholly-owned acquisition subsidiaries of CSQ
Holding Company that will merge with and into Quinton and Cardiac
Science, respectively. As part of the transaction, Quinton will
also merge into CSQ Holding Company. Cardiac Science and Quinton
intend to cause CSQ Holding Company to file a registration
statement on Form S-4 containing a proxy statement/prospectus in
connection with the merger transaction. Investors and security
holders are urged to read this filing when it becomes available
because it will contain important information about the
transaction. Investors and security holders may obtain free copies
of these documents (when they are available) and other documents
filed with the Securities and Exchange Commission at the Securities
and Exchange Commission's web site at http://www.sec.gov/. In
addition, investors and security holders may obtain free copies of
the documents filed with the Securities and Exchange Commission by
Cardiac Science by contacting Cardiac Science Investor Relations at
(949)-474-4300. Investors and security holders may obtain free
copies of the documents filed with the Securities and Exchange
Commission by Quinton by contacting Quinton Investor Relations at
(425) 402-2009. Cardiac Science and its directors and executive
officers may be deemed to be participants in the solicitation of
proxies from the stockholders of Cardiac Science in connection with
the mergers. Information regarding the special interests of these
directors and executive officers in the transaction described
herein will be included in the joint proxy statement/prospectus of
Cardiac Science and Quinton described above. Additional information
regarding the directors and executive officers of Cardiac Science
is also included in the Cardiac Science proxy statement for its
2004 Annual Meeting of Stockholders, which was filed with the
Securities and Exchange Commission on or about November 22, 2004.
This document is available free of charge at the Securities and
Exchange Commission's web site at http://www.sec.gov/ and from
Cardiac Science by contacting Cardiac Science Investor Relations at
(949) 474-4300. Quinton and its directors and executive officers
also may be deemed to be participants in the solicitation of
proxies from the stockholders of Quinton in connection with the
mergers. Information regarding the special interests of these
directors and executive officers in the transaction described
herein will be included in the joint proxy statement/prospectus of
Cardiac Science and Quinton described above. Additional information
regarding these directors and executive officers is also included
in Quinton's proxy statement for its 2004 Annual Meeting of
Stockholders, which was filed with the Securities and Exchange
Commission on or about April 14, 2004. This document is available
free of charge at the Securities and Exchange Commission's web site
at http://www.sec.gov/ and from Quinton by contacting Quinton
Investor Relations at (425) 402-2009. This press release includes
forward-looking statements. These statements may be identified by
the use of forward-looking terminology such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "might," "plan," "potential," "predict," "should," or
"will," or the negative thereof or other variations thereon or
comparable terminology. Quinton and Cardiac Science have based
these forward-looking statements on the current expectations,
assumptions, estimates and projections. While Quinton and Cardiac
Science believe these expectations, assumptions, estimates and
projections are reasonable, such forward-looking statements are
only predictions and involve known and unknown risks and
uncertainties, many of which are beyond our control. Certain
factors, including those discussed in Quinton's Quarterly Report on
Form 10-Q for the quarter ended September 30, 2004, under the
heading "Certain Factors That May Affect Future Results," and in
Cardiac Sciences' Prospectus dated February 7, 2005, filed pursuant
to Rule 424b(3), under the heading "Risk Factors," may cause the
actual results, performance or achievements to differ materially
from any future results, performance or achievements expressed or
implied by these forward-looking statements. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. We do not undertake any obligation
to update any such statements or to publicly announce the results
of any revisions to any such statements to reflect future events or
developments. For Cardiac Science Investors Matt Clawson
(Investors) Len Hall (Media) Allen & Caron Inc (949) 474-4300
Cardiac Science Roderick de Greef EVP and CFO (949) 797-3800
Quinton Cardiology Systems Mike Matysik Sr. Vice President and CFO
(425) 402-2009 DATASOURCE: Cardiac Science, Inc.; Quinton
Cardiology Systems, Inc. CONTACT: Investors, Matt Clawson, or
Media, Len Hall, both of Allen & Caron Inc, +1-949-474-4300,
for Cardiac Science Investors; or Roderick de Greef, EVP and CFO of
Cardiac Science, +1-949-797-3800; or Mike Matysik, Sr. Vice
President and CFO of Quinton Cardiology Systems, +1-425-402-2009
Web site: http://www.quinton.com/ Web site:
http://www.cardiacscience.com/
Copyright
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jul 2023 to Jul 2024